CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni Sells 4,293 Shares

CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni sold 4,293 shares of the firm’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $198,680.04. Following the sale, the chief executive officer now directly owns 226,540 shares of the company’s stock, valued at $10,484,271.20. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

CRISPR Therapeutics Trading Up 0.5 %

Shares of CRSP traded up $0.22 during trading hours on Tuesday, reaching $48.05. 867,601 shares of the stock traded hands, compared to its average volume of 1,461,021. CRISPR Therapeutics AG has a 52-week low of $37.55 and a 52-week high of $91.10. The company’s 50-day moving average price is $47.13 and its two-hundred day moving average price is $53.77. The company has a market cap of $4.08 billion, a P/E ratio of -17.43 and a beta of 1.68.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Monday, August 5th. The company reported ($1.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.06). The company had revenue of $0.52 million for the quarter, compared to the consensus estimate of $12.31 million. During the same quarter last year, the business posted ($0.98) EPS. The business’s quarterly revenue was down 99.3% compared to the same quarter last year. On average, research analysts forecast that CRISPR Therapeutics AG will post -5.6 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Needham & Company LLC reduced their price target on shares of CRISPR Therapeutics from $88.00 to $84.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th. Rodman & Renshaw assumed coverage on shares of CRISPR Therapeutics in a research report on Friday, August 2nd. They set a “buy” rating and a $90.00 price target for the company. Piper Sandler reaffirmed an “overweight” rating and issued a $105.00 target price on shares of CRISPR Therapeutics in a research report on Monday, June 17th. Truist Financial cut their target price on shares of CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a research report on Monday, August 12th. Finally, StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a research report on Friday, August 16th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $75.19.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Riggs Asset Managment Co. Inc. lifted its stake in CRISPR Therapeutics by 66.7% in the 1st quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company’s stock worth $34,000 after purchasing an additional 200 shares in the last quarter. Global Trust Asset Management LLC lifted its stake in CRISPR Therapeutics by 150.0% in the 2nd quarter. Global Trust Asset Management LLC now owns 500 shares of the company’s stock worth $27,000 after purchasing an additional 300 shares in the last quarter. Larson Financial Group LLC lifted its stake in CRISPR Therapeutics by 95.5% in the 2nd quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock worth $31,000 after purchasing an additional 276 shares in the last quarter. NBC Securities Inc. lifted its stake in CRISPR Therapeutics by 257.6% in the 1st quarter. NBC Securities Inc. now owns 608 shares of the company’s stock worth $41,000 after purchasing an additional 438 shares in the last quarter. Finally, GPS Wealth Strategies Group LLC lifted its stake in CRISPR Therapeutics by 99.7% in the 2nd quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock worth $33,000 after purchasing an additional 307 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.